Neuraxis, INC

NRXS NYSE CIK: 0001933567

Company Information

Industry Electromedical & Electrotherapeutic Apparatus
SIC Code 3845
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 11611 N. MERIDIAN ST, CARMEL, IN, 46032
Mailing Address 11611 N. MERIDIAN ST, CARMEL, IN, 46032
Phone (812) 689-0791
Fiscal Year End 1231
EIN 455079684

Financial Overview

FY2025

$3.00M
Total Liabilities
$-0.95
EPS

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 19, 2026 View on SEC
4 Insider stock transaction report March 2, 2026 View on SEC
4 Insider stock transaction report February 26, 2026 View on SEC
4 Insider stock transaction report February 26, 2026 View on SEC
4 Insider stock transaction report February 26, 2026 View on SEC
4 Insider stock transaction report February 26, 2026 View on SEC
4 Insider stock transaction report February 26, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 3, 2026 View on SEC
4 Insider stock transaction report January 30, 2026 View on SEC

Annual Reports

10-K March 19, 2026
  • Achieved $12.5 million in sales in 2023, a significant 150% jump driven by the Neuro-Modulator System launch.
  • Secured FDA approval in August 2023 for the Neuro-Modulator System to treat nerve pain after shingles.
View Analysis

Insider Trading

STRONG BUY 2 insiders 3 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 3845)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.